With your own knowledge and the help of the following document:

Document 1 (Title: Cutaneous Manifestations of Hepatic Porphyrias): Porphyria cutanea tarda (PCT) represents the most common human porphyria, arising from reduced activity of uroporphyrinogen decarboxylase (UROD), the fifth enzyme in the heme biosynthetic pathway. Both acquired (approximately 80% of cases) and hereditary forms exist, with the acquired variant typically requiring additional environmental or metabolic triggers for clinical expression. The pathophysiological hallmark involves hepatic accumulation of uroporphyrinogen and other carboxylated porphyrinogens, which undergo oxidation to corresponding porphyrins. These water-soluble photosensitizing molecules are excreted in urine, imparting a characteristic dark brown or burgundy coloration. The principal cutaneous manifestations result from porphyrin deposition in the skin, where photoactivation by long-wavelength ultraviolet light (400-410 nm) generates reactive oxygen species, causing complement activation and dermal-epidermal junction damage. Clinical features include vesiculobullous eruptions on sun-exposed sites (particularly dorsal hands and forearms), facial hypertrichosis, hyperpigmentation, and skin fragility with secondary erosions and scarring. Milia formation and dyspigmentation commonly accompany healing lesions. Unlike acute hepatic porphyrias, neurovisceral symptoms are notably absent. Multiple precipitating factors have been identified, including excess iron, alcohol consumption, estrogens, hepatitis C infection, HIV, and certain hepatotoxins. Therapeutic approaches target different aspects of disease pathophysiology. Iron reduction via therapeutic phlebotomy represents the cornerstone of treatment, even in patients with normal ferritin levels, as iron plays a critical role in catalyzing uroporphyrinogen oxidation and inhibiting residual UROD activity. Standard regimens involve weekly or biweekly phlebotomy (removing 450-500 mL of blood) until achievement of relative iron deficiency, indicated by serum ferritin below 20 ng/mL or mild anemia. Alternative therapeutic approaches include low-dose hydroxychloroquine, which complexes with porphyrins to facilitate their excretion, though this may transiently exacerbate symptoms.
Document 2 (Title: Clinical Manifestations of Thyroid Hormone Deficiency): Hypothyroidism represents a common endocrine disorder with diverse manifestations reflecting thyroid hormone's fundamental role in multiple physiological processes. Laboratory evaluation reveals characteristic patterns, with reduced serum free T4 levels representing a diagnostic hallmark across various hypothyroid etiologies. The condition produces distinctive metabolic effects including significant thermoregulatory changes, with affected individuals demonstrating reduced basal metabolic rate and heat production resulting in cold intolerance and documented hypothermia in more severe cases. Energy metabolism alterations manifest clinically as progressive fatigue and characteristic weight changes despite unchanged or reduced caloric intake, with most patients experiencing 10-20 pound weight increases during disease development. Cardiovascular manifestations include bradycardia, mild hypertension, and occasionally pericardial effusions in advanced cases. Neuropsychiatric symptoms predominate in many presentations, featuring cognitive slowing, memory impairment, and depressive symptoms rather than anxiety or nervousness, which more typically characterize hyperthyroid states. Gastrointestinal motility reduction commonly produces constipation, while dermatological changes include characteristic skin dryness, hair thinning, and non-pitting edema from glycosaminoglycan accumulation. Particularly significant laboratory findings beyond thyroid function tests include dyslipidemia, with elevated total cholesterol, LDL-C, and triglycerides resulting from reduced hepatic LDL receptor expression and diminished cholesterol clearance. This consistent hypercholesterolemia represents an important metabolic consequence requiring monitoring during treatment. Comprehensive management requires addressing both the underlying thyroid dysfunction and associated metabolic derangements through appropriate hormone replacement therapy and monitoring of clinical and biochemical parameters during treatment.
Document 3 (Title: Growth promoting effects of IGF-1): The first demonstration that exogenous IGF-1 stimulates growth was the administration of purified hormone to hypophysectomised rats. After the biosynthesis of IGF-1 identical to the native hormone, trials of its use in humans were begun; first in adults and then in children. Our group was the first to introduce long term administration of biosynthetic IGF-1 to children with primary IGF-1 deficiency—primary GH insensitivity or LS. The finding that daily IGF-1 administration raises serum alkaline phosphatase, which is an indicator of osteoblastic activity, and serum procollagen, in addition to IGFBP-3, led to long term treatment. Treatment of patients with LS was also initiated in other parts of the world. The difference between us and the other groups was that we used a once daily dose, whereas the others administered IGF-1 twice daily. Table 1 compares the linear growth response of children with LS treated by four different groups. It can be seen that before treatment the mean growth velocity was 3–4.7 cm/year and that this increased after IGF-1 treatment to 8.2–9.1 cm/year, followed by a lower velocity of 5.5–6.4 cm/year in the next two years. (In GH treatment the highest growth velocity registered is also in the first year of treatment.) Figure 5 illustrates the growth response to IGF-1 in eight children during the first years of treatment. Ranke and colleagues reported that two of their patients had reached the third centile (Tanner), as did the patient of Krzisnik and Battelino; however, most patients did not reach a normal final height. The reasons may be late initiation of treatment, irregular IGF-1 administration, underdosage, etc. Ranke et al conclude that long term treatment of patients with LS promoted growth and, if treatment is started at an early age, there is a considerable potential for achieving height normalisation. Because no patient in our group was treated since early infancy to final height we cannot confirm this opinion. When the growth response to GH treatment in infants with IGHD was compared with that of IGF-1 in infants with LS we found that the infants with IGHD responded faster and better than those with LS. However, the small number of patients and the differences in growth retardation between the two groups makes it difficult to reach a conclusion. Both hormones stimulated linear growth, but GH seemed more effective than IGF-1. One cause may be the greater growth deficit of the infants with LS than those with IGHD, an insufficient dose of IGF-1, or that there is a need for some GH to provide an adequate stem cell population of prechondrocytes to enable full expression of the growth promoting action of IGF-1, as postulated by Green and colleagues and Ohlson et al. All the above findings based on a few clinical studies with small groups of patients and a few experimental studies remain at present controversial. The crucial question is whether there are any, and if so, whether there are sufficient IGF-1 receptors in the “progenitor cartilage zone” of the epiphyseal cartilage to respond to endocrine and exogenous IGF-1. Using the mandibular condyle of 2 day old ICR mice, Maor et al showed that these condyles, which resemble the epiphyseal plates of the long bones, contain IGF-1 and high affinity IGF-1 receptors also in the chondroprogenitor cell layers, which enables them to respond to IGF-1 in vitro. Sims et al, using mice with GH receptor KO, showed that IGF-1 administration stimulates the growth (width) of the tibial growth plate and that IGF-1 has a GH independent effect on the growth plate. These findings are similar to those found when treating hypophysectomised rats with IGF-1. In conclusion, IGF-1 is an important growth hormone, mediating the anabolic and linear growth promoting effect of pituitary GH protein. It has a GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimised by the synergistic action with GH.

Answer the following multiple-choice question.
Question: A 48-year-old woman comes to the emergency department because of a photosensitive blistering rash on her hands, forearms, and face for 3 weeks. The lesions are not itchy. She has also noticed that her urine has been dark brown in color recently. Twenty years ago, she was successfully treated for Coats disease of the retina via retinal sclerotherapy. She is currently on hormonal replacement therapy for perimenopausal symptoms. Her aunt and sister have a history of a similar skin lesions. Examination shows multiple fluid-filled blisters and oozing erosions on the forearms, dorsal side of both hands, and forehead. There is hyperpigmented scarring and patches of bald skin along the sides of the blisters. Laboratory studies show a normal serum ferritin concentration. Which of the following is the most appropriate next step in management to induce remission in this patient?
Options:
A. Pursue liver transplantation
B. Begin oral thalidomide therapy
C. Begin phlebotomy therapy
D. Begin oral hydroxychloroquine therapy

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ← if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.